These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
167 related articles for article (PubMed ID: 32972190)
21. Body mass index and insulin-like growth factor 1 as risk factors for discordant growth hormone and insulin-like growth factor 1 levels following pituitary surgery in acromegaly. Zhang S; Li Y; Guo X; Gao L; Lian W; Yao Y; Feng M; Bao X; Wang R; Xing B J Formos Med Assoc; 2018 Jan; 117(1):34-41. PubMed ID: 28341329 [TBL] [Abstract][Full Text] [Related]
22. Cardiac abnormalities in acromegaly. Pathophysiology and implications for management. Vitale G; Pivonello R; Lombardi G; Colao A Treat Endocrinol; 2004; 3(5):309-18. PubMed ID: 15330678 [TBL] [Abstract][Full Text] [Related]
23. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. Colao A; Baldelli R; Marzullo P; Ferretti E; Ferone D; Gargiulo P; Petretta M; Tamburrano G; Lombardi G; Liuzzi A J Clin Endocrinol Metab; 2000 Jan; 85(1):193-9. PubMed ID: 10634386 [TBL] [Abstract][Full Text] [Related]
24. Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management. Sharma AN; Tan M; Amsterdam EA; Singh GD Clin Cardiol; 2018 Mar; 41(3):419-425. PubMed ID: 29574794 [TBL] [Abstract][Full Text] [Related]
25. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance. Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582 [TBL] [Abstract][Full Text] [Related]
26. Impact of disease duration on coronary calcification in patients with acromegaly. Herrmann BL; Severing M; Schmermund A; Berg C; Budde T; Erbel R; Mann K Exp Clin Endocrinol Diabetes; 2009 Sep; 117(8):417-22. PubMed ID: 19373755 [TBL] [Abstract][Full Text] [Related]
27. Acromegalic cardiomyopathy: a review of the literature. Matta MP; Caron P Pituitary; 2003; 6(4):203-7. PubMed ID: 15237931 [TBL] [Abstract][Full Text] [Related]
28. Cardiac resynchronization therapy improves heart failure in one patient with acromegaly-induced cardiomyopathy: a case report. Wang JY; Hu YM; Liu JX; Luo XJ J Med Case Rep; 2019 Apr; 13(1):106. PubMed ID: 31018862 [TBL] [Abstract][Full Text] [Related]
29. Cardiovascular comorbidities in acromegaly: an update on their diagnosis and management. Ramos-Leví AM; Marazuela M Endocrine; 2017 Feb; 55(2):346-359. PubMed ID: 28042644 [TBL] [Abstract][Full Text] [Related]
31. Associations of coefficient of variation of serum GH with previous radiotherapy, hypopituitarism and cardiac disease in patients with treated acromegaly. Jayasena CN; Izzi-Engbeaya C; Narayanaswamy S; Modi M; Clarke H; Nijher GM; Meeran K; Dhillo WS Clin Endocrinol (Oxf); 2015 Jun; 82(6):870-5. PubMed ID: 25439593 [TBL] [Abstract][Full Text] [Related]
32. Post-treatment heterogeneity of cardiometabolic risk in patients with acromegaly: The impact of GH and IGF-1. Heydari M; Hashemi-Madani N; Emami Z; Khajavi A; Ghorbani M; Malek M; Ataei Kachuee M; Khamseh ME Endocr Res; 2022 Feb; 47(1):1-7. PubMed ID: 34102938 [TBL] [Abstract][Full Text] [Related]
33. Acromegaly with Normal Insulin-Like Growth Factor-1 Levels and Congestive Heart Failure as the First Clinical Manifestation. Lee HM; Lee SH; Yang IH; Hwang IK; Hwang YC; Ahn KJ; Chung HY; Hwang HJ; Jeong IK Endocrinol Metab (Seoul); 2015 Sep; 30(3):395-401. PubMed ID: 25491785 [TBL] [Abstract][Full Text] [Related]
34. Increased circulating levels of irisin are associated with cardiovascular risk factors in subjects with acromegaly. Calan M; Demirpence M Hormones (Athens); 2019 Dec; 18(4):435-442. PubMed ID: 31696447 [TBL] [Abstract][Full Text] [Related]
35. Suspected silent pituitary somatotroph neuroendocrine tumor associated with acromegaly-like bone disorders: a case report. Xiao T; Mao X; Wang O; Yao Y; Deng K; Zhu H; Duan L BMC Endocr Disord; 2024 Jul; 24(1):121. PubMed ID: 39044175 [TBL] [Abstract][Full Text] [Related]
36. The role of cumulative growth hormone exposure in determining mortality and morbidity in acromegaly: a single centre study. Varadhan L; Reulen RC; Brown M; Clayton RN Pituitary; 2016 Jun; 19(3):251-61. PubMed ID: 26724807 [TBL] [Abstract][Full Text] [Related]
37. Role of growth hormone in chronic heart failure: therapeutic implications. Volterrani M; Giustina A; Manelli F; Cicoira MA; Lorusso R; Giordano A Ital Heart J; 2000 Nov; 1(11):732-8. PubMed ID: 11110515 [TBL] [Abstract][Full Text] [Related]
38. Cardiac effect of thyrotoxicosis in acromegaly. Marzullo P; Cuocolo A; Ferone D; Pivonello R; Salvatore M; Lombardi G; Colao A J Clin Endocrinol Metab; 2000 Apr; 85(4):1426-32. PubMed ID: 10770177 [TBL] [Abstract][Full Text] [Related]
39. Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. Marzullo P; Di Somma C; Pratt KL; Khosravi J; Diamandis A; Lombardi G; Colao A; Rosenfeld RG J Clin Endocrinol Metab; 2001 Jul; 86(7):3001-8. PubMed ID: 11443159 [TBL] [Abstract][Full Text] [Related]
40. Cardiac and metabolic effects of chronic growth hormone and insulin-like growth factor I excess in young adults with pituitary gigantism. Bondanelli M; Bonadonna S; Ambrosio MR; Doga M; Gola M; Onofri A; Zatelli MC; Giustina A; degli Uberti EC Metabolism; 2005 Sep; 54(9):1174-80. PubMed ID: 16125529 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]